GlassScriptPhysician profile
Heather A Brewer
NPI 1306225586
$4,829.38
in general payments reported to CMS, 2019-2025
31 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $549 · 2022: $874 · 2023: $1,001 · 2024: $998 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,406.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,011.99 | 2022-2025 | Proclaim, Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $897.00 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $648.77 | 2021-2025 | Xtampza |
| Scilex Pharmaceuticals INC. | $538.20 | 2021-2025 | Ztlido |
| Indivior INC. | $201.75 | 2023-2025 | Sublocade |
| Amgen INC. | $156.00 | 2021-2022 | |
| Axsome Therapeutics, INC. | $140.61 | 2025 | Symbravo |
| Mml US, INC. | $119.52 | 2023-2025 | Reactiv8 |
| Almatica Pharma LLC | $89.91 | 2021-2023 | Gralise |
| Pfizer INC. | $88.31 | 2024-2025 | |
| Uswm, LLC | $81.96 | 2023 | Zimhi, Lucemyra |
| Lilly USA, LLC | $78.78 | 2021-2022 | |
| Spr Therapeutics, INC | $71.63 | 2023-2025 | Sprint Pns System |
| Braeburn INC. | $70.48 | 2024-2025 | Brixadi |
| Averitas Pharma INC. | $65.76 | 2023-2024 | Qutenza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $64.00 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.22 | 2022 | |
| Spinal Simplicity, LLC | $54.82 | 2023-2024 | Ha Minuteman G3-R |
| Ibsa Pharma INC. | $52.74 | 2023-2024 | Tirosint, Licart, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.94 | 2025 | Relistor |
| Nevro Corp. | $48.79 | 2021-2022 | |
| Redhill Biopharma INC. | $45.52 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $36.78 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $29.46 | 2022-2023 | Seglentis |
| Lundbeck LLC | $24.96 | 2023 | Vyepti |
| Si-Bone, INC. | $22.23 | 2024 | |
| Medtronic, INC. | $21.33 | 2025 | Synchromedii |
| Biodelivery Sciences International, INC. | $17.89 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.90 | 2024 | Horizant |
| Fidia Pharma USA INC. | $12.09 | 2021 | |
| Eisai INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.